Abstract 913MO
Background
Nasopharyngeal carcinoma (NPC) survivors have an increased risk of second primary cancer (SPC) after definitive radiotherapy. It has been speculated that the routine use of intensity-modulated radiotherapy (IMRT) further increases the risk of radiation-associated SPC, but long-term clinical data with reference to population cancer incidences are lacking.
Methods
This is a territory-wide multicentered study. Consecutive NPC patients (n=3166) who underwent definitive IMRT in all six public oncology centers in Hong Kong between 2001 and 2010 were included. SPC risks were quantified by standardized incidence ratios (SIR) and absolute excess risks (AER), estimated from age-, sex- and calendar year-specific population cancer incidence data from the Hong Kong Cancer Registry. Predictive factors for SPC occurrence were analyzed by Cox regression. SPC-specific mortality was estimated using competing risk model.
Results
With a median follow-up of 10.8 years, 290 SPCs were observed with a crude incidence of 9.2%. Cancer risk in NPC survivors was 90% higher than that in general population (SIR, 1.9; 95% CI, 1.7–2.2), with an AER of 52.1 (95% CI, 36.8–67.3) per 10,000 person-years at risk. Significant excess cancer risks were observed for oral cavity (SIR, 26.3; 95% CI, 19.1–33.6), soft tissue or bone sarcoma (SIR, 15.2; 95% CI, 9.3–21.2), oropharynx (SIR, 11.4; 95% CI, 4.0–18.9), paranasal sinus (SIR, 8.6; 95% CI, 1.7-25.1), salivary gland (SIR, 6.8; 95% CI, 1.4-20.0), non-melanoma skin (SIR, 3.6; 95% CI, 1.5–5.7), thyroid (SIR, 3.4; 95% CI, 1.2–5.6) and lung (SIR, 1.8; 95% CI, 1.3–2.3). Advanced age, smoking, hepatitis B status and re-irradiation were independent predictive factors for SPC occurrence. SPC constituted 9.4% of all deaths during study period, the 5-year and 10-year SPC-specific mortality were 0.9% and 3.4% respectively. Median overall survival after SPC occurrence was 2.4 years.
Conclusions
Second cancer risk after IMRT for NPC was substantial within the irradiated head and neck regions. Relative risk of SPC after IMRT was comparable with historical reports in the conventional 2-dimensional radiotherapy era. SPC impairs long-term survival of NPC patients, close surveillance is warranted as part of survivorship care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Health and Medical Research Fund, The Government of the Hong Kong Special Administrative Region.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
912MO - A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study
Presenter: Li Zhang
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
914MO - Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial
Presenter: Christian Borel
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
915MO - Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Richard Greil
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
916MO - Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC)
Presenter: Charu Aggarwal
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
917MO - TOPNIVO - A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): Final analysis
Presenter: Caroline Even
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
918MO - Molecular enrichment and outcomes based on ESCAT levels in metastatic salivary gland tumours (mSGT) patients (pts) treated in early clinical trials
Presenter: Alberto Hernando-Calvo
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
919MO - ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
Presenter: Renata Ferrarotto
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Laura Locati
Session: Mini Oral - Head & neck cancer
Resources:
Slides
Invited Discussant 912MO, 913MO and 914MO
Presenter: Pierre Blanchard
Session: Mini Oral - Head & neck cancer
Resources:
Slides
Webcast
Invited Discussant 915MO, 916MO and 917MO
Presenter: Ana Martins Ferreira Castro
Session: Mini Oral - Head & neck cancer
Resources:
Slides
Webcast